Advances in prognostic models for osteosarcoma risk

被引:2
|
作者
Yao, Yi [1 ,2 ]
Wang, Dapeng [1 ]
Zheng, Li [1 ,2 ,4 ]
Zhao, Jinmin [1 ,2 ,3 ]
Tan, Manli [1 ,2 ,4 ]
机构
[1] Guangxi Med Univ, Guangxi Engn Ctr Biomed Mat Tissue & Organ Regene, Affiliated Hosp 1, Nanning 530021, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Collaborat Innovat Ctr Regenerat Med & Med Bioreso, Nanning 530021, Peoples R China
[3] Guangxi Med Univ, Dept Orthoped, Affiliated Hosp 1, Nanning 530021, Peoples R China
[4] Guangxi Med Univ, Life Sci Inst, Nanning 530021, Peoples R China
基金
中国国家自然科学基金;
关键词
Osteosarcoma; Risk -prognosis model; TUMOR-SUPPRESSOR; CELL-PROLIFERATION; OVARIAN CANCERS; DNA METHYLATION; DOWN-REGULATION; UP-REGULATION; EXPRESSION; PROTEIN; INVASION; RECEPTORS;
D O I
10.1016/j.heliyon.2024.e28493
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The risk prognosis model is a statistical model that uses a set of features to predict whether an individual will develop a specific disease or clinical outcome. It can be used in clinical practice to stratify disease severity and assess risk or prognosis. With the advancement of large-scale secondgeneration sequencing technology, along Prognosis models for osteosarcoma are increasingly being developed as large-scale second-generation sequencing technology advances and clinical and biological data becomes more abundant. This expansion greatly increases the number of prognostic models and candidate genes suitable for clinical use. This article will present the predictive effects and reliability of various prognosis models, serving as a reference for their evaluation and application.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Recent advances in adjuvant therapies of osteosarcoma
    KonttinenYrjo
    SantavirtaSeppo
    中国临床药理学与治疗学杂志, 1999, (01) : 52 - 57
  • [32] Animal models of osteosarcoma
    Fan, Timothy M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (08) : 1327 - 1338
  • [33] Advances in limb salvage treatment of osteosarcoma
    Yang, Yichun
    Han, Lei
    He, Zewei
    Li, Xiaojuan
    Yang, Suping
    Yang, Jifei
    Zhang, Ya
    Li, Dongqi
    Yang, Yihao
    Yang, Zuozhang
    JOURNAL OF BONE ONCOLOGY, 2018, 10 : 36 - 40
  • [34] Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
    Wu, Kunzhe
    Yu, Beibei
    Li, Di
    Tian, Yangyang
    Liu, Yan
    Jiang, Jinlan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [35] Biology and therapeutic advances for pediatric osteosarcoma
    Marina, N
    Gebhardt, M
    Teot, L
    Gorlick, R
    ONCOLOGIST, 2004, 9 (04): : 422 - 441
  • [37] Prognostic models for mortality risk in patients requiring ECMO
    Pladet, Lara C. A.
    Barten, Jaimie M. M.
    Vernooij, Lisette M.
    Kraemer, Carlos V. Elzo
    Bunge, Jeroen J. H.
    Scholten, Erik
    Montenij, Leon J.
    Kuijpers, Marijn
    Donker, Dirk W.
    Cremer, Olaf L.
    Meuwese, Christiaan L.
    INTENSIVE CARE MEDICINE, 2023, 49 (02) : 131 - 141
  • [38] Prognostic models for mortality risk in patients requiring ECMO
    Lara C. A. Pladet
    Jaimie M. M. Barten
    Lisette M. Vernooij
    Carlos V. Elzo Kraemer
    Jeroen J. H. Bunge
    Erik Scholten
    Leon J. Montenij
    Marijn Kuijpers
    Dirk W. Donker
    Olaf L. Cremer
    Christiaan L. Meuwese
    Intensive Care Medicine, 2023, 49 : 131 - 141
  • [39] MFNG is an independent prognostic marker for osteosarcoma
    Yi Gao
    Lili Luo
    Yuxing Qu
    Qi Zhou
    European Journal of Medical Research, 28
  • [40] Survivin as a prognostic factor for osteosarcoma patients
    Osaka, Eiji
    Suzuki, Takashi
    Osaka, Shunzo
    Yoshida, Yukihiro
    Sugita, Hideyuki
    Asami, Satoru
    Tabata, Keiichi
    Hemmi, Akihiro
    Sugitani, Masahiko
    Nemoto, Norimichi
    Ryu, Junnosuke
    ACTA HISTOCHEMICA ET CYTOCHEMICA, 2006, 39 (03) : 95 - 100